Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders
Cardiology Research and Practice · 17.04.2021 · 2021 · 1-7
DOI: 10.1155/2021/6637799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Research and Practice, erschienen am 17.04.2021. Verfasst von Wiktor Kuliczkowski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Wroclaw Medical University, Wrocław, Poland. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw Medical University.
Abstract (Originalsprache)
Background
Platelet reactivity and response to antiplatelet drugs, acetylsalicylic acid (ASA) and clopidogrel, in patients with thrombocytopenia and thrombocythemia can have a potentially important effect on the outcome. The effectiveness and safety of antiplatelet drugs in such patients has not been well examined. Measuring the effect of ASA and clopidogrel on platelets could help guide the therapy. Nevertheless, platelet response to antiplatelet drugs is not routinely measured in platelet count disorders and relevant evidence is scarce.
Aims
The study aimed to measure platelet reactivity and response to ASA and clopidogrel in patients with platelet count disorders. Materials and Methods. This was a cross-sectional study of consecutive patients hospitalized in cardiology and hematology departments in the years 2018–2019. The study included patients with thrombocytopenia (PLT < 150 G/L) and thrombocythemia (PLT > 450 G/L) on ASA or dual antiplatelet therapy (DAPT; ASA plus clopidogrel). Controls included patients on antiplatelet drugs with normal platelet count. Platelet reactivity was measured in whole blood (Multiplate aggregometer, Roche, Switzerland) using arachidonic acid (AA), adenosine-5′-diphosphate (ADP), and thrombin receptor agonist peptide-6 (TRAP) as agonists. Platelet aggregation was expressed in arbitrary units (AU). AA-induced aggregation was used as a measure of response to ASA with a cut-off above 30 AU showing high on-treatment platelet reactivity to ASA (HTPR-A). ADP-induced aggregation measured response to clopidogrel with a cut-off above 48 AU for high on-treatment platelet reactivity to clopidogrel (HTPR-C). TRAP-induced aggregation measured baseline platelet reactivity not affected by oral antiplatelet drugs.
Results
The study included 174 patients. There were 64 patients with thrombocytopenia, 30 patients with chronic thrombocythemia, and 80 controls. All patients were on 75 mg of ASA and 32% of them additionally on 75 mg of clopidogrel due to a history of recent coronary artery angioplasty. AA- and ADP-induced aggregation was comparable between thrombocytopenic patients and controls (median (IQR) 19 (7–28) vs. 23 (15–38) for AA AU and 32 (16–44) vs. 50 (32–71) for ADP AU, respectively), while it was significantly higher in thrombocythemic patients (median (IQR) 80 (79–118) for AA AU and 124 (89–139) for ADP AU). TRAP-induced aggregation showed significantly lowest aggregation in thrombocytopenic (median (IQR) 41 (34–60) for TRAP AU) and highest in thrombocythemic patients (median (IQR) 137 (120–180) for TRAP AU). HTPR-A was frequent in thrombocythemic patients in comparison with thrombocytopenic patients and controls (60% vs. 4% vs. 15%, respectively; p < 0.0002 ). HTPR-C was highly common in thrombocythemic patients and least common in thrombocytopenic ones in comparison with controls (80% vs. 8% vs. 40%, respectively; p < 0.001 ).
Conclusion
Chronic thrombocytopenia does not significantly affect platelet reactivity and response to ASA and clopidogrel in comparison with controls. Thrombocytosis significantly increases platelet reactivity and attenuates response to both ASA and clopidogrel.
Autor:innen und Institutionen
- Department of Cardiology, Wroclaw Medical University, Wrocław, Poland.
- Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Wrocław, Poland.
- Department of Toxicology, Wroclaw Medical University, Wrocław, Poland.
- Department of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wrocław, Poland.
ORCID-Profile: Wiktor Kuliczkowski, Konrad Kaaz
Förderung
- Wroclaw Medical University
Zitieren
APA
Kuliczkowski, W., Żurawska-Płaksej, E., Podolak-Dawidziak, M., Cielecka-Prynda, M., Karolko, B., Dębski, J., Kaaz, K., Protasiewicz, M., Prajs, I., Mysiak, A., Wróbel, T., & Usnarska-Zubkiewicz, L. (2021). Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders. Cardiology Research and Practice, 2021, 1-7. https://doi.org/10.1155/2021/6637799
Vancouver
Kuliczkowski W, Żurawska-Płaksej E, Podolak-Dawidziak M, Cielecka-Prynda M, Karolko B, Dębski J, et al. Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders. Cardiology Research and Practice. 2021;2021:1-7. doi:10.1155/2021/6637799
BibTeX
@article{Kuliczkowski2021,
author = {Kuliczkowski, Wiktor and Żurawska-Płaksej, Ewa and Podolak-Dawidziak, Maria and Cielecka-Prynda, Magdalena and Karolko, Bożena and Dębski, Jakub and Kaaz, Konrad and Protasiewicz, Marcin and Prajs, Iwona and Mysiak, Andrzej and Wróbel, Tomasz and Usnarska-Zubkiewicz, Lidia},
title = {Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders},
journal = {Cardiology Research and Practice},
year = {2021},
volume = {2021},
pages = {1--7},
doi = {10.1155/2021/6637799}
}
EUVIMED